HBCo — Hofseth Biocare ASA Income Statement
0.000.00%
Last trade - 00:00
- NOK838.61m
- NOK982.08m
- NOK194.87m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 67.8 | 69.3 | 87.6 | 120 | 195 |
Cost of Revenue | |||||
Gross Profit | 0.825 | 13.7 | 2.51 | 28.5 | 44.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 147 | 161 | 206 | 249 | 297 |
Operating Profit | -79.6 | -92 | -119 | -129 | -103 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -89.2 | -102 | -126 | -137 | -107 |
Provision for Income Taxes | |||||
Net Income After Taxes | -89.2 | -102 | -126 | -137 | -107 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -89.2 | -102 | -126 | -137 | -107 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -89.2 | -102 | -126 | -137 | -107 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.29 | -0.3 | -0.347 | -0.363 | -0.331 |
Dividends per Share |